GOVX (Geovax Labs) Short Interest


GOVX Geovax Labs Inc GOVX
22 GF Score
Price $1.31
! 3 Warning Signs
View Full Analysis

What is Geovax Labs Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

GOVX vs BIVI, KAPA, BCDA: Short Interest Comparison

For the Biotechnology subindustry, Geovax Labs's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geovax Labs Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Short Interest distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Short Interest falls into.


GOVX
22GF Score
Geovax Labs Inc GOVX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geovax Labs Business Description

Address 1955 Lake Park Drive, Suite 300, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score

Get the complete analysis for GOVX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.31
Price